Literature DB >> 9439147

Association between genetic polymorphisms of the cytochromes P-450 (1A1, 2D6, and 2E1) and the susceptibility to pancreatic cancer.

H C Lee1, Y B Yoon, C Y Kim.   

Abstract

OBJECTIVES: Metabolic activation is a prerequisite for the carcinogenic effect of many carcinogens, and considerable interindividual variation exists in the metabolic capacity to activate the carcinogens. The cytochromes P-450 (CYPs) are responsible for the activation mechanism, and polymorphisms of the CYPs (CYP1A1, CYP2D6, and possibly CYP2E1) are known to be related to increased susceptibility to smoking related Kreyberg type I lung cancer. The aim of this study is to clarify the relationship of genetic polymorphisms of the CYPs to susceptibility to pancreatic cancer, another smoking-related cancer.
METHODS: We analyzed 45 samples from patients with pancreatic cancer and 53 samples from controls. DNA was isolated from blood samples and the CYP1A1, 2D6 and 2E1 genes were amplified by PCR. Analyzing the genotypes of the CYPs by allele-specific PCR or RFLP analysis, we assessed the allele frequencies for each mutation of the CYPs among the patients with pancreatic cancer and the controls.
RESULTS: The allele frequencies for the mutation in the 3'-flanking region of the CYP1A1 among the cases and the controls were 0.31 and 0.36, respectively. The allele frequencies for the exon 7 mutation of the CYP1A1 were 0.16 and 0.23, respectively, but with no statistical significance. The frequencies for the mutant c2 allele of the CYP2E1 were 0.19 and 0.30, respectively, but with no statistical significance. Two persons homozygous for a gene deletion of the CYP2D6 were observed among control subjects; other mutations were not observed among either the patients or controls.
CONCLUSION: We could not find any evidence that polymorphisms of the CYPs are associated with increased susceptibility to pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9439147      PMCID: PMC4531995          DOI: 10.3904/kjim.1997.12.2.128

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  28 in total

Review 1.  Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanisms of regulation.

Authors:  C S Yang; J S Yoo; H Ishizaki; J Y Hong
Journal:  Drug Metab Rev       Date:  1990       Impact factor: 4.518

2.  Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene.

Authors:  K Kawajiri; K Nakachi; K Imai; A Yoshii; N Shinoda; J Watanabe
Journal:  FEBS Lett       Date:  1990-04-09       Impact factor: 4.124

3.  Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene.

Authors:  S Hayashi; J Watanabe; K Nakachi; K Kawajiri
Journal:  J Biochem       Date:  1991-09       Impact factor: 3.387

4.  Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose.

Authors:  K Nakachi; K Imai; S Hayashi; J Watanabe; K Kawajiri
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

Review 5.  Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes.

Authors:  F P Guengerich; T Shimada
Journal:  Chem Res Toxicol       Date:  1991 Jul-Aug       Impact factor: 3.739

Review 6.  Enzymatic activation of chemicals to toxic metabolites.

Authors:  F P Guengerich; D C Liebler
Journal:  Crit Rev Toxicol       Date:  1985       Impact factor: 5.635

7.  Functional significance of different human CYP1A1 genotypes.

Authors:  F Crofts; E Taioli; J Trachman; G N Cosma; D Currie; P Toniolo; S J Garte
Journal:  Carcinogenesis       Date:  1994-12       Impact factor: 4.944

8.  An investigation of whether polymorphisms of cytochrome P4502E1 are genetic markers of susceptibility to alcoholic end-stage organ damage in a Chinese population.

Authors:  Y C Chao; T H Young; W K Chang; H S Tang; C T Hsu
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

9.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

10.  Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA 1535/pSK1002.

Authors:  T Shimada; M Iwasaki; M V Martin; F P Guengerich
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

View more
  6 in total

1.  Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer.

Authors:  Donghui Li; Li Jiao; Yanan Li; Mark A Doll; David W Hein; Melissa L Bondy; Douglas B Evans; Robert A Wolff; Renato Lenzi; Peter W Pisters; James L Abbruzzese; Manal M Hassan
Journal:  Carcinogenesis       Date:  2005-06-29       Impact factor: 4.944

Review 2.  Smoking-gene interaction and disease development: relevance to pancreatic cancer and atherosclerosis.

Authors:  Xing Li Wang; Jian Wang
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

Review 3.  Molecular epidemiology of pancreatic cancer.

Authors:  Donghui Li; Li Jiao
Journal:  Int J Gastrointest Cancer       Date:  2003

4.  Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk of pancreatic adenocarcinoma.

Authors:  G Liu; P Ghadirian; D Vesprini; N Hamel; A J Paradis; G Lal; S Gallinger; S A Narod; W D Foulkes
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

Review 5.  An overview of genetic polymorphisms and pancreatic cancer risk in molecular epidemiologic studies.

Authors:  Yingsong Lin; Kiyoko Yagyu; Naoto Egawa; Makoto Ueno; Mitsuru Mori; Haruhisa Nakao; Hiroshi Ishii; Kozue Nakamura; Kenji Wakai; Satoyo Hosono; Akiko Tamakoshi; Shogo Kikuchi
Journal:  J Epidemiol       Date:  2010-11-06       Impact factor: 3.211

6.  Functional PstI/RsaI polymorphism in CYP2E1 is associated with the development, progression and poor outcome of gastric cancer.

Authors:  Jin Feng; Xiaolin Pan; Junbo Yu; Zheng Chen; Hao Xu; Wael El-Rifai; Guoxin Zhang; Zekuan Xu
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.